First Horizon Advisors Inc. Has $172,000 Holdings in ICON Public Limited (NASDAQ:ICLR)

First Horizon Advisors Inc. raised its position in shares of ICON Public Limited (NASDAQ:ICLR) by 33.9% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 597 shares of the medical research company’s stock after acquiring an additional 151 shares during the period. First Horizon Advisors Inc.’s holdings in ICON Public were worth $172,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ICLR. SkyView Investment Advisors LLC acquired a new stake in shares of ICON Public in the first quarter valued at $1,021,000. EverSource Wealth Advisors LLC grew its holdings in ICON Public by 17.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after acquiring an additional 42 shares during the last quarter. GAMMA Investing LLC increased its position in ICON Public by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares in the last quarter. ORG Partners LLC bought a new position in shares of ICON Public in the second quarter worth about $59,000. Finally, Liontrust Investment Partners LLP lifted its position in shares of ICON Public by 19.5% during the second quarter. Liontrust Investment Partners LLP now owns 119,728 shares of the medical research company’s stock worth $37,531,000 after purchasing an additional 19,546 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Stock Up 0.7 %

Shares of NASDAQ:ICLR opened at $214.25 on Friday. The company has a 50 day moving average price of $257.93 and a two-hundred day moving average price of $297.63. The company has a market capitalization of $17.67 billion, a PE ratio of 23.89, a PEG ratio of 1.57 and a beta of 1.25. ICON Public Limited has a 52 week low of $183.38 and a 52 week high of $347.72. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the business posted $3.10 EPS. Analysts forecast that ICON Public Limited will post 13.42 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on ICLR shares. Redburn Atlantic began coverage on shares of ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 price target for the company. TD Cowen lowered their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Leerink Partnrs raised ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. Truist Financial lowered their price objective on ICON Public from $363.00 to $295.00 and set a “buy” rating for the company in a research report on Monday, October 28th. Finally, Leerink Partners restated an “outperform” rating and set a $255.00 target price (down from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.45.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.